CONSIDERATIONS TO KNOW ABOUT HEMGENIX

Amount of eligible people: CDEC reviewed the uncertainty in the amount of people with moderately severe to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some clients who are labeled as having gentle or reasonable sickness could have a intense bleeding phenotype, which m